# East Bay Biotech Map - Validation & Quality Control Log

**PURPOSE**: Consolidated validation reports tracking data quality, completeness, and enhancement opportunities across geography, focus areas, websites, and addresses.

**AUDIENCE**: Project owner (Jaden) - quality control reference

**Last Updated**: November 8, 2025

---

## Table of Contents

1. [Overview & Quality Metrics](#overview--quality-metrics)
2. [Geographic Data Validation](#geographic-data-validation)
3. [Focus Area Quality Assessment](#focus-area-quality-assessment)
4. [Website URL Validation](#website-url-validation)
5. [Address Consolidation History](#address-consolidation-history)
6. [Focus Area Mapping & Enhancement Opportunities](#focus-area-mapping--enhancement-opportunities)
7. [Action Plan & Priorities](#action-plan--priorities)

---

## Overview & Quality Metrics

### Dataset Snapshot (as of November 8, 2025)

| Metric | Value | Status |
|--------|-------|--------|
| Total Companies | 280 ‚Üí **319** (final) | ‚úÖ Expanded |
| Companies with Addresses | 165 (58.9%) ‚Üí **319 (100%)** | ‚úÖ Complete |
| Companies with Focus Areas | 280 (100%) | ‚úÖ Complete |
| Focus Area Quality (100+ chars) | 97 (34.6%) | ‚ö†Ô∏è Needs improvement |
| Website URL Coverage | 271 (99%) | ‚úÖ Excellent |
| HTTPS Protocol Usage | 270/271 (99.6%) | ‚úÖ Excellent |
| Unique Cities Covered | 43 | ‚úÖ Good coverage |

---

## Geographic Data Validation

**Generated**: November 8, 2025
**Source**: validation_geography.md (407 lines)

### Key Findings

#### Data Completeness
- **Total Companies**: 280
- **Companies with Addresses**: 165 (58.9% at time of validation)
- **Companies Missing Addresses**: 115 (41.1%)
- **Unique Cities**: 43 across Bay Area

**Current Status**: ‚úÖ **100% address coverage achieved** (319 companies post-merge)

#### City Distribution (Top 15 Biotech Hubs)

| City | Count | Cluster Type |
|------|-------|--------------|
| South San Francisco | 34 | Primary biotech hub |
| San Francisco | 27 | Second largest cluster |
| Berkeley | 25 | University/research-affiliated |
| Redwood City | 23 | Corporate headquarters hub |
| Emeryville | 22 | Life sciences cluster |
| Palo Alto | 14 | Peninsula pharma hub |
| San Carlos | 12 | Peninsula biotech cluster |
| Alameda | 11 | Manufacturing/services hub |
| Fremont | 11 | South Bay manufacturing |
| Menlo Park | 11 | Life sciences/pharma hub |
| Hayward | 10 | South Bay services |
| Pleasanton | 9 | East Bay biotech |
| San Jose | 8 | South Bay hub |
| Mountain View | 7 | Peninsula tech companies |
| Brisbane | 4 | Gene editing cluster |

#### Data Quality Issues Identified & Resolved

**City Name Standardization**: ‚úÖ GOOD
- No abbreviations or inconsistent formatting detected
- Standard convention and capitalization throughout

**City Mismatch Issues** (5 companies - RESOLVED):

1. **Accelero Biostructures**
   - Listed City: San Francisco | Address City: CA
   - Resolution: Confirmed San Francisco location

2. **Actym Therapeutics**
   - Listed City: Berkeley | Address City: San Francisco
   - Resolution: Updated to San Francisco (per address)

3. **Altay Therapeutics**
   - Listed City: San Francisco | Address City: San Bruno
   - Resolution: Updated to San Bruno

4. **Amber Bio**
   - Listed City: Berkeley | Address City: San Francisco
   - Resolution: Updated to San Francisco

5. **Pliant Therapeutics**
   - Listed City: Redwood City | Address City: South San Francisco
   - Resolution: Updated to South San Francisco

**Data Entry Error** (FIXED):
- FibroGen had "https://www.fibrogen.com" in City field instead of "San Francisco"

#### Geographic Scope Insights

**Core Bay Area Coverage**: South San Francisco, Berkeley, Emeryville remain top 3 biotech hubs

**Expansion to Outlier Cities**: Coverage includes less common biotech areas like Livermore, Orinda, Danville, Larkspur, Half Moon Bay, Morgan Hill - demonstrating comprehensive regional mapping

---

## Focus Area Quality Assessment

**Generated**: November 8, 2025
**Source**: validation_focus_areas.md (694 lines), VALIDATION_QUICK_REFERENCE.txt (160 lines)

### Critical Quality Metrics

| Metric | Value | Status |
|--------|-------|--------|
| Companies with Focus Areas | 280/280 (100%) | ‚úÖ Complete |
| Average Description Length | 53 characters | ‚ùå Too short |
| Desired Minimum Length | 100+ characters | Target |
| Current Compliance (100+ chars) | 97 companies (34.6%) | ‚ö†Ô∏è Critical issue |
| Very Generic Descriptions | 26 companies | ‚ùå Poor quality |
| Weak/Underdeveloped Descriptions | 78 companies | ‚ùå Needs work |
| **Total with Quality Issues** | **104 companies (37.1%)** | ‚ö†Ô∏è Major gap |

### Length Distribution

| Category | Count | Percentage | Assessment |
|----------|-------|------------|------------|
| <50 chars (Too Short) | 183 | 65.4% | ‚ùå PROBLEM |
| 50-200 chars (Acceptable) | 97 | 34.6% | ‚úÖ Acceptable |
| 200+ chars (Rich) | 0 | 0.0% | ‚ö†Ô∏è Missing |

### Performance by Company Stage

| Stage | Companies | Avg Length | % Too Short | Severity |
|-------|-----------|------------|-------------|----------|
| Pre-clinical/Startup | 137 | 38 chars | 89% | ‚ùå CRITICAL |
| Tools/Services/CDMO | 38 | 41 chars | 84% | ‚ùå CRITICAL |
| Large Pharma | 7 | 70 chars | 43% | ‚ö†Ô∏è Concerning |
| Commercial-Stage | 35 | 76 chars | 34% | ‚ö†Ô∏è Concerning |
| Clinical-Stage | 44 | 78 chars | 27% | ‚ö†Ô∏è Medium |

### Examples: Poor vs. Excellent Descriptions

**POOR EXAMPLES (Current State)**:
- 1cBio: "Small molecule drug discovery" (26 chars) - TOO GENERIC
- Kimia: "AI/ML Drug Discovery Platform" (32 chars) - TOO VAGUE
- Amaros: "Ophthalmology data platform (AI)" (30 chars) - LACKS DETAIL
- Acrobat: "CRISPR-based drug discovery" (27 chars) - NO SPECIFICS
- Nanotein: "Protein-based Reagents for Cell Therapy" (39 chars) - MINIMAL

**EXCELLENT EXAMPLES (Model Standard)**:
- Arsenal Bio: "Programmable cell therapies for solid tumors. Advanced protein and genetic engineering of T-cells." (98 chars)
- Allogene: "Allogeneic CAR T (AlloCAR T‚Ñ¢) therapies. Protein engineering of CAR constructs is critical." (89 chars)

### V2 Enrichment Opportunity

- **Companies in FOCUS_AREA_MAPPING_V2.md**: 54
- **Overlap with CSV dataset**: 49
- **HIGH-PRIORITY ENHANCEMENT CANDIDATES**: 41
- **V2 companies NOT in CSV (naming mismatch)**: 5

**Enhancement Impact**: 14.6% of dataset (41 companies) could be improved with existing V2 data, representing 2-5x richer descriptions per company.

### Quality Standards Going Forward

‚úÖ **Requirements**:
- Minimum description length: 100 characters
- Must include: Specific disease/application area
- Must include: Key technology or mechanism
- Should include: Proprietary platform names (if applicable)
- Format: Single coherent statement or 2-3 focused sentences

‚ùå **Terminology to AVOID**:
- "Platform" (alone, without specifics)
- "Drug discovery" (too generic)
- "Therapeutics" (without modality)
- "Technologies" (without detail)

‚úÖ **Preferred Patterns**:
- "Engineered [protein type] for [mechanism]"
- "[Modality] targeting [specific target/pathway]"
- "[Technology platform]‚Ñ¢ enabling [application]"
- "[Mechanism] for [disease/indication]"

---

## Website URL Validation

**Generated**: November 8, 2025
**Source**: validation_websites.md (72 lines)

### Summary Statistics

| Metric | Value | Status |
|--------|-------|--------|
| Total Companies in Dataset | 271 | - |
| HTTPS URLs (secure) | 270 | ‚úÖ 99.6% |
| HTTP URLs (insecure) | 1 | ‚ö†Ô∏è 0.4% |
| URLs with Format Issues | 0 | ‚úÖ Perfect |

### Protocol Usage

- **HTTPS (secure)**: 270 URLs - Best practice ‚úÖ
- **HTTP (insecure)**: 1 URL - Needs upgrade ‚ö†Ô∏è

### Issues Identified & Resolved

#### High Priority Issue (FIXED):
**Upgrade HTTP to HTTPS**:
- Atreca: Changed `http://atreca.com` ‚Üí `https://atreca.com`

#### Medium Priority - Shared Domain URLs

**3 domains shared by multiple companies** (possible acquisitions or duplicates):

1. **acurex.com**: AcureX Biosciences, AcureX Therapeutics
2. **ancorabiotech.com**: Ancora Biotech, Ancora Bio
3. **atum.bio**: ATUM, ATUM (DNA2.0)

**Recommendation**: Verify if these are acquisitions, parent companies, or duplicate entries

### Ongoing Maintenance Recommendations

- Quarterly validation of all URLs
- Monitor for domain changes or company acquisitions
- Automated URL checking with `curl -I https://url.com`
- Test domain reachability periodically

---

## Address Consolidation History

**Generated**: November 8, 2025
**Source**: CONSOLIDATION_REPORT.txt (60 lines)

### Consolidation Process Summary

**Objective**: Consolidate address findings from multiple batch files and update companies.csv

**Data Sources Merged**:
1. addresses_batch1.json - 20 addresses
2. addresses_batch2.json - 18 addresses
3. addresses_found.json - 26 addresses (from first pass)
4. **Total unique addresses found**: 45 companies

### Results

**CSV Update Status**:

| Metric | Before | After | Change |
|--------|--------|-------|--------|
| Companies WITH addresses | 150 (53.6%) | 165 (58.9%) | +15 (+5.4%) |
| Companies WITHOUT addresses | 130 (46.4%) | 115 (41.1%) | -15 |
| **Completion percentage** | 53.6% | **58.9%** | +5.4% |

**Duplicate Handling**:
- Duplicate addresses removed: 39 (from original 84 total entries)
- Final unique address entries: 45

### Sample of Companies Updated

‚úì Akero Therapeutics ‚Üí 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080
‚úì Aligos Therapeutics ‚Üí 1 Corporate Drive, 2nd floor, South San Francisco, CA 94080
‚úì Altos Labs ‚Üí 2600 Bridge Parkway, Redwood City, CA 94065
‚úì Adverum Biotechnologies ‚Üí 100 Cardinal Way, Redwood City, CA 94063
‚úì Alamar Biosciences ‚Üí 47071 Bayside Pkwy, Fremont, CA 94538

### Final Status

**Current State**: ‚úÖ **100% address coverage achieved** (all 319 companies have addresses)

---

## Focus Area Mapping & Enhancement Opportunities

**Source**: FOCUS_AREA_MAPPING_V2.md (775 lines)

### Overview

Comprehensive focus area mapping with enhanced descriptions for 54 companies across priority tiers.

**Sources Referenced**:
- TXT: Data from biotech_companies_A.txt
- PDF: Data from biotech_companies_gem.pdf
- BOTH: Data merged from both sources

### Company Categorization by Technology Tier

#### TIER 1: CRISPR/GENE EDITING (6 companies)

**Core companies with enhanced descriptions**:

1. **Acrigen Biosciences** (Berkeley)
   - Enhanced: Advanced gene editing platform combining next-generation CRISPR enzymes (Œ±Cas and ŒºCas families) with engineered anti-CRISPR proteins (ErAcrs)

2. **Acrobat Genomics** (San Carlos)
   - Platform utilizing CRISPR technology for systematic target discovery

3. **Addition Therapeutics** (Berkeley/South San Francisco)
   - RNA-only therapeutics platform using PRINT‚Ñ¢ technology for RNA-mediated transgene insertion

4. **Amber Bio** (Berkeley/San Francisco)
   - First-of-its-kind RNA writing platform capable of multi-kilobase genetic edits

5. **Caribou Biosciences** (Berkeley)
   - Clinical-stage CRISPR-based allogeneic cell therapies using hybrid RNA-DNA guides

6. **Scribe Therapeutics** (Alameda)
   - Engineering bespoke CRISPR enzymes and delivery systems (co-founded by Jennifer Doudna)

#### TIER 2: ANTIBODY DISCOVERY & THERAPEUTICS (15+ companies)

**Highlighted companies**:

1. **Abalone Bio** (Emeryville)
   - Functional antibody discovery for GPCRs using FAST platform with AI-guided design

2. **Acepodia** (Alameda)
   - Antibody-Cell Conjugation (ACC‚Ñ¢) technology using biorthogonal chemistry

3. **Adanate** (Alameda)
   - Antibody therapeutics targeting LILRB family for immuno-oncology

**Additional Antibody Companies**: Aarvik Therapeutics, Ab Studio, AbTherx, AbboMax, Accurus Biosciences, Antibodies Incorporated, Antibody Solutions, and more

### Enhancement Priority

**41 HIGH-PRIORITY CANDIDATES** identified for description enhancement using V2 mapping data

**5 NAMING MISMATCHES** to resolve:
- 4D Molecular Therapeutics
- Catalent (possible acquisition)
- Ginkgo Bioworks
- JBEI (Joint BioEnergy Institute)
- Phyllom BioProducts

---

## Action Plan & Priorities

### 90-Day Quality Improvement Plan (28-34 Hours Total Effort)

#### PRIORITY 1: V2 Integration (Week 1-2) - 4-6 Hours
- ‚úÖ Integrate V2 enrichment for 41 candidate companies
- ‚úÖ Fix 5 naming mismatches
- **Impact**: 14.6% of dataset greatly improved

#### PRIORITY 2: Focus Area Standardization (Week 3-4) - 6-8 Hours
- [ ] Standardize 104 weak/generic descriptions to ‚â•100 chars
- [ ] Research company websites and press releases
- **Impact**: 37% of dataset meets quality baseline

#### PRIORITY 3: Schema Definition (Week 5-6) - 3-4 Hours
- [ ] Define description schema by company category
- [ ] Apply consistent structure (Technology + Disease + Mechanism)
- **Impact**: Consistency across all categories

#### PRIORITY 4: Advanced Tagging (Week 7-8) - 6-8 Hours
- [ ] Extract proprietary technology platform names
- [ ] Assign Technology Cluster tags
- [ ] Assign Protein Science Relevance Tiers
- **Impact**: Enable advanced filtering and discovery

### Immediate Actions

1. ‚úÖ Address all geographic city mismatches (5 companies)
2. ‚úÖ Upgrade HTTP URL to HTTPS (Atreca)
3. ‚úÖ Fix FibroGen city field data entry error
4. [ ] Integrate 41 V2 enhanced descriptions
5. [ ] Establish minimum 100-character description standard
6. [ ] Resolve 5 naming mismatches

### Expected Outcomes

| Phase | Inadequate Descriptions | Status |
|-------|------------------------|--------|
| Current State | 65% | ‚ö†Ô∏è Baseline |
| After Priority 1 | 50% | üîÑ 41 companies improved |
| After Priority 2 | 15% | üîÑ Weak descriptions fixed |
| Final State | <5% | ‚úÖ Target |

---

## User Experience Improvement

### Before Quality Enhancement
> User reads "Small molecule drug discovery" and cannot differentiate between 100+ similar companies; must research independently.

### After Quality Enhancement
> User reads "Small-molecule drug discovery platform targeting transcription factors for inflammation and cancer. Structure-based design focus." and immediately understands company positioning.

---

## Validation Methodology Notes

### Geographic Validation
- City name standardization check across all entries
- Address format validation (Street, City, State ZIP)
- City-address consistency verification
- Geographic outlier identification

### Focus Area Validation
- Description length analysis
- Quality assessment (generic vs. specific)
- Technology categorization
- Cross-reference with V2 enrichment data

### Website Validation
- Protocol verification (HTTP vs. HTTPS)
- Format validation (valid domain structure)
- Duplicate domain detection
- **Note**: Network reachability testing performed separately in production environment

### Address Consolidation
- Deduplication across multiple batch sources
- Format standardization
- Completeness tracking
- Quality verification through manual spot-checks

---

**Report Compiled**: November 8, 2025
**Next Review**: February 8, 2026 (Quarterly)
**Maintained By**: Jaden Shirkey
